Ambulance heat may not spoil life-saving bleeding treatments
NCT ID NCT07646964
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether two blood-clotting products — human fibrinogen and freeze-dried plasma — remain stable when stored in an ambulance under everyday conditions, including summer heat. Researchers in Graz, Austria, will compare samples stored in the ambulance with ones kept under ideal conditions over four months. The goal is to see if current storage practices in emergency vehicles are good enough to keep these products effective for treating severe bleeding.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- human fibrinogen (Fibryga) and lyophilized human plasma (Octaplas LG AB)
- What this could lead to
- If these products remain stable, it could confirm that current ambulance storage practices are safe for emergency bleeding treatments.
- What could go wrong
- This is a very small observational study (only 2 samples) in one city, so results may not apply to other settings or climates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
no study population
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Fibryga samples stored in the participating ground-based EMS ambulance. * Octaplas LG AB samples stored in the participating ground-based EMS ambulance. * Samples available for laboratory analysis at the predefined study time points. * Samples exposed to routine operational storage conditions during the study period. Exclusion Criteria: * Samples with damaged packaging. * Samples with incomplete storage documentation. * Samples accidentally removed from the designated storage system during the observation period. * Samples unavailable for laboratory analysis. * Samples exposed to conditions not representative of routine EMS operation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Exanguination are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.